What did @de3xpilled actually say?
The creator ran through what they framed as a joke side-effect list, claiming peptides made them lean and fit into size 28 jeans, then admitted it was a bit before getting to the real answer. Their actual position: "I haven't faced any side effects off of" BPC-157 or GHK-Cu. The one exception was retatrutide, where starting at 1.5 milligrams caused frequent bathroom trips. That's the whole disclosure.
To be fair, the format is casual and clearly not a clinical report. But 53,000 people watched this, and several of them are probably making decisions based on it. The implicit message is that peptide therapy is essentially side-effect-free, with the only real bump being a minor GI issue from an aggressive first dose. That framing deserves scrutiny.
Does the science back this up?
Partially, but with significant gaps. GHK-Cu has a relatively favorable safety profile in the literature, and BPC-157 animal studies suggest low acute toxicity, but human trial data is thin. The claim of zero side effects is hard to evaluate because the evidence base is still immature.
GHK-Cu (copper peptide) has been studied for wound healing and anti-inflammatory effects. Pickart and Margolina (2018, Biomolecules) reviewed its regenerative properties and noted no significant adverse events in cosmetic and topical applications. However, systemic injectable use is a different exposure route, and that data is sparse. BPC-157 has been studied extensively in rodent models, with Sikiric et al. (2018, Current Pharmaceutical Design) noting gastroprotective and tissue-healing effects, but controlled human trials are essentially nonexistent. Extrapolating from rat studies to "no side effects in humans" is a leap. As for retatrutide, that is an experimental GLP-1/GIP/glucagon receptor tri-agonist studied by Eli Lilly. The GI effects the creator described, frequent restroom use, are consistent with documented GI adverse events in Jastreboff et al. (2023, New England Journal of Medicine), where nausea, diarrhea, and vomiting were among the most common complaints.
What did they get wrong (or right)?
They got one thing right: starting retatrutide at 1.5 milligrams and experiencing GI distress tracks with what the clinical literature shows. That's an honest, if incomplete, disclosure. What they got wrong is treating personal tolerance as a general conclusion.
Saying "I've been totally fine" is an N-of-1 anecdote. Individual variation in peptide response is real. BPC-157 lacks any peer-reviewed human safety trials sufficient to draw conclusions from. GHK-Cu has better tolerability data but mostly from topical routes. More importantly, the video does not mention that the peptides being used are not FDA-approved for the indications implied, that sourcing matters enormously for purity and contamination risk, or that absence of noticed side effects does not mean absence of physiological effects. The creator also casually names retatrutide alongside BPC-157 and GHK-Cu as if they belong in the same category. They do not. Retatrutide is a structurally and pharmacologically distinct investigational drug, not a peptide in the recovery-and-optimization sense.
What should you actually know?
The honest answer is that nobody knows the full side-effect profile of these compounds in humans at the doses people are actually using, because that research hasn't been done. That is the real story here, not that the effects are zero.
For GHK-Cu, topical applications appear safe based on available data, but injectable systemic use has no comparable evidence base. For BPC-157, animal data is promising but animal-to-human translation in peptide pharmacology has a poor track record. Retatrutide is a separate conversation entirely. It is an investigational compound whose trial data shows meaningful GI side effects, potential heart rate increases, and unknown long-term consequences. Jastreboff et al. (2023, NEJM) showed 17.5 percent average body weight loss in trials but also documented adverse event rates that were not trivial. Anyone using this compound outside a clinical trial setting is taking on real, unquantified risk. The sourcing issue also cannot be ignored. Compounded peptides vary in purity, and contamination from improper synthesis is a documented concern. One person's "no side effects" experience may reflect good sourcing, good genetics, short duration of use, or simply not recognizing subclinical effects.
The bottom line
This video presents a best-case personal experience as though it generalizes. It doesn't. The science on BPC-157 and GHK-Cu is genuinely interesting but genuinely incomplete. Retatrutide is a different animal entirely and shouldn't be lumped in casually. Personal anecdote from one lean person on TikTok is not a safety profile.